The global neonatal conjunctivitis therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Conjunctivitis is a kind of eye condition, which is commonly known as pink eye since the inflammation due to the infection makes the white part of the eye look red/pink. Neonatal conjunctivitis is also known as ophthalmia neonatorum. Neonatal conjunctivitis occurs in infants within the first 28 days of birth. In the first place, the disease gets acquired during the passage of the neonate through the infected birth canal. Some of the common microorganisms that cause the infection include Chlamydia trachomatis, Staphylococcus aureus, Staphylococcus epidermis, Escherichia coli, Neisseria gonorrhoea, other gram-negative bacteria and Herpes Simplex Virus.

Another factor contributing to the market growth includes the increasing awareness among the global population that surge the demand for treatment of neonatal conjunctivitis. As a result, several biopharmaceutical companies have planned to invest in R&D initiatives to novel drugs and therapies for the treatment of this disorder. For instance, in July 2020, Zhaoke Ophthalmology Pharmaceutical Ltd. and IACTA Pharmaceuticals signed an agreement to accelerate the development of drugs called IC 265 and IC 270. The former is developed to treat dry eye and the latter for ocular allergy.

Some key players operating in the market include Merck & Co. Inc., Akorn Inc, Pfizer Inc., Bayer AG, among others. These players are aiming at strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Merck & Co. Inc., Akorn Inc, Pfizer Inc., Bayer AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Neonatal Conjunctivitis Therapeutics Market by Segment

By Treatment Administration 

• Oral

• Topical

• Intramuscular and Intravenous

By Distribution Channel 

• Hospital Pharmaciess

• Retail Pharmacies

• Drug Stores

• E-Commerce

Global Neonatal Conjunctivitis Therapeutics Market  by Region